Prosecution Insights
Last updated: July 17, 2026
Application No. 18/565,537

A method for asymmetric synthesis of (-)- Anisomelic Acid

Non-Final OA §112
Filed
May 17, 2024
Priority
Jun 10, 2021 — nonprovisional of PCTCN2021099492
Examiner
HABTE, KAHSAY
Art Unit
Tech Center
Assignee
Cns Biotek Corp.
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1371 granted / 1612 resolved
+25.0% vs TC avg
Moderate +7% lift
Without
With
+7.4%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 8m
Avg Prosecution
74 currently pending
Career history
1650
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
3.7%
-36.3% vs TC avg
§102
9.0%
-31.0% vs TC avg
§112
63.9%
+23.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1612 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-8 are pending in this application. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-8 ae rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 and claims dependent thereon are rejected because the definition of “R…..is alkoxy group, aromatic oxygen group, alkylamine group, alkyl sulfhydryl group, aromatic sulfhydryl group, or silicon group” is indefinite. What is covered and what is not? How can one tell if a given alkoxy group, aromatic oxygen group, alkylamine group, alkyl sulfhydryl group, aromatic sulfhydryl group, or silicon group is not part of the claim? What are the exact definition of R for compound (E)-5? For compound (Z)-5? Note that the final product is a single compound with a carboxylic acid (i.e. R is -OH). What is aromatic oxygen group, alkylamine group, alkyl sulfhydryl group, aromatic sulfhydryl group, or silicon group? What is covered and what is not? The examiner recommends that applicants recite specific definitions of R to overcome this rejection. Claim Objections Claim 1 is objected to because of the following informalities: The chemical structures in claim 1 are not legible. Some of the bonds are faded and are not connected fully. PNG media_image1.png 503 614 media_image1.png Greyscale Note that compounds 2 and 3 in claim 7 are drawn properly. PNG media_image2.png 160 532 media_image2.png Greyscale Appropriate correction is required. Specification The disclosure is objected to because of the following informalities: The chemical structure at page 3 of the specification is not legible. The bonds are faded. It is recommended that applicants fix the problem. PNG media_image3.png 253 286 media_image3.png Greyscale In the drawings, the reaction scheme in Figure 4 is not clear. The bonds are faded. PNG media_image4.png 272 669 media_image4.png Greyscale The same problem appears in Figure 7 and Figure 9. PNG media_image5.png 226 713 media_image5.png Greyscale PNG media_image6.png 223 692 media_image6.png Greyscale It is recommended that applicants redraw the chemical structures, so that the bonds and substituents are clear. Appropriate correction is required. Conclusion 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte Ph.D. whose telephone number is (571)272-0667. The examiner can normally be reached on 8:30 - 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY MURRAY can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Kahsay Habte/ Primary Examiner, Art Unit 1624 June 3, 2026
Read full office action

Prosecution Timeline

May 17, 2024
Application Filed
Jul 31, 2024
Response after Non-Final Action
Jun 08, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679805
NOVEL BIOACTIVE SUBSTANCE EXHIBITING ANTIMALARIAL ACTIVITY, AND USE FOR SAME
2y 10m to grant Granted Jul 14, 2026
Patent 12673961
COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS
3y 4m to grant Granted Jul 07, 2026
Patent 12673940
METHODS OF MANUFACTURE AND SYNTHESIS OF FLUORESCENT DYE COMPOUNDS AND USES THEREOF
2y 4m to grant Granted Jul 07, 2026
Patent 12662474
FUSED RING DERIVATIVES CONTAINING 1,4-OXAZEPANE
2y 10m to grant Granted Jun 23, 2026
Patent 12655158
BIOMIMETIC G-QUARTET COMPOUNDS
3y 8m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
92%
With Interview (+7.4%)
1y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1612 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month